For all infants born before 29 weeks gestation, palivizumab is recommended for the first year of life during respiratory syncytial virus season to reduce the likelihood of hospitalization.
For all infants born before 29 weeks gestation, palivizumab is recommended for the first year of life during respiratory syncytial virus season to reduce the likelihood of hospitalization.